Lianhuan Pharmaceutical announced that it has received the Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notice for argatroban API from the National Medical Products Administration. The packaging specifications include 1 kg per bag, 2 kg per bag, and 5 kg per bag. Argatroban is a direct thrombin inhibitor, and its injection is indicated for improving neurological symptoms and daily activities in the acute phase of ischemic cerebral infarction, as well as improving symptoms associated with chronic arterial occlusive disease.
Jiangsu Lianhuan Pharmaceutical Co LtdReceived marketing approval for argatroban API from NMPA, enabling commercial sale.